Using cyclodextrins to prevent aggregation in protein formulations has been known for some time, and we have already published a lot about this topic.
This paper from Florian Johann, Steffen Wöll, and Henning Gieseler adds some special spice to the application as they investigate the potential of CDs in reducing aggregation of Antibody–Drug Conjugates with different payloads.
The main takeaways of the study are:
Hydroxypropylated (CDs) reduced agitation-induced aggregation in all tested ADCs without causing destabilization during incubation at 40 °C.
Native CDs that are not surface active partially reduced agitation-induced aggregation in ADCs, suggesting the possibility of stabilizing mechanisms beyond mere competition at the air-liquid interface.
ADC-specific formulation effects were observed, e.g., superior performance of the large HPγCD type in stabilizing a highly unstable ADC with a bulky fluorophore payload during incubation.
Today’s cyclodextrin paper by CarboHyde CSO Milo Malanga PhD, in collaboration with former colleagues from Cyclolab R&D Ltd. and Budapest University of Technology and Economics, sheds light on the potential of cyclodextrins to inhibit bacterial communication through quorum sensing.
Quorum sensing is vital for bacteria to coordinate activities, but inhibiting this process can be a game-changer in combating bacterial infectivity. Cyclodextrins encapsulate signal molecules, disrupting bacterial communication and, consequently, the expression of virulence factors.
Excitingly, our research shows that cyclodextrins exhibit a notable inhibitory effect on the quorum-sensing system of A. fischeri. The impact varies with alkyl chain length, with alkylthio substitution amplifying inhibition and quaternary ammonium groups mitigating it. These findings highlight cyclodextrins’ potential as a promising therapeutic avenue for treating bacterial infections.
As a company also involved in research for Alzheimer’s disease both from the DDS and API perspective, we cheer for this news!
The U.S. Food and Drug Administration (FDA) has approved Kisunla™ (donanemab-azbt), a once-monthly injection (350 mg/20 mL) for IV infusion developed by Eli Lilly and Company.
Kisunla is designed to treat adults with early symptomatic Alzheimer’s disease (AD), which includes mild cognitive impairment (MCI) and mild dementia stages of AD, with confirmed amyloid pathology. This is the first and only amyloid plaque-targeting therapy that allows stopping treatment when amyloid plaques are cleared, potentially reducing costs and the number of infusions needed.
Today’s cyclodextrin this recent patent of RemeGen Biosciences suggests that cyclodextrins, particularly methyl-beta-cyclodextrin (Fine Chemicals – www.carbohydesolutions.com) can significantly improve the efficacy of antibody-drug conjugates so that some of the ADC drugs with safety issues caused by excessive dosage can be developed. Moreover, due to the reduction in the dosage of ADC drugs, the cost of production and treatment for patients have also been significantly reduced, thereby being beneficial.
Transformational Potential: Cell and gene therapies are revolutionizing how we treat diseases, promising to cure certain conditions. They remain at the forefront of healthcare innovation.
Fast-Growing Field: These therapies are the fastest-growing therapeutics areas, with over 50 new in vivo and ex vivo gene therapy launches planned in the next few years.
Challenges and Innovation: While promising, cell and gene therapies require substantial innovation to unlock their full potential for patients. Scaling digital and analytics in discovery and R&D is part of the solution.
Market Resilience: Despite the disruptions caused by the pandemic, stakeholders, including CGT innovators, healthcare providers, and CDMOs, are optimistic that positive developments lie ahead.
Viral-Vector Therapies: Viral-vector gene therapies are here to stay, but addressing challenges and strategizing for patient access is critical for their success.
Overall, the outlook is positive, but ongoing research, regulatory advancements, and manufacturing innovations will shape the future of cell and gene therapy. 🌟
Today’s cyclodextrin is this great patent from Roquette‘s team, Tao Peng, Lucas Goh, Jeff Chang Shih Chieh on a new class of Lipid nanoparticles (LNPs) that can be used for nucleic acid delivery, wherein LNPs comprise a nucleic acid and a nonionic or cationic cyclodextrin compound.
How do you see the future of CDs in gene therapy? Will we see solutions commercialized in the future? In GENEGUT we certainly work towards this goal!
In this work and using kneading, we have compared the encapsulation of progesterone, a lipophilic hormone used in hormone replacement therapy, with β-CD and Nanosponges. The project opens the door to new medical formulations of progesterone, supporting the ball-milling kneading as an exciting way of making complexes.
Our next free webinar, titled “Cyclodextrin formulations: The Journey from the Benchtop to the Patients” brings together experts who will guide us through the milestones of this remarkable journey.
Event Overview: Join us for an illuminating webinar that traces the evolution of cyclodextrin-based drug delivery systems—from laboratory research to real-world patient care. Our esteemed speakers will explore key aspects of this journey, highlighting breakthroughs, challenges, and the promise of cyclodextrins in improving therapeutic outcomes.
Time&Date: September 26., 2024, 3 pm – 5 pm (CEST, Budapest time)
Agenda:
Preparation of Parenteral and Oral Cyclodextrin-Based Formulations and Their Physical CharacterizationSpeaker: Dr. Carmen Popescu (Roquette) – Dr. Popescu will unveil the meticulous process of formulating cyclodextrin-based drugs for parenteral and oral administration. From solubility enhancement to stability studies, discover how cyclodextrins bridge the gap between lab experiments and clinical applications.
Cyclodextrins in Liquid, Transdermal, and Other Non-Traditional FormsSpeaker: Dr. Balazs Kondoros (CarboHyde) – Dr. Kondoros will guide us beyond conventional dosage forms. Explore how cyclodextrins revolutionize liquid formulations, transdermal patches, and other innovative delivery methods. Witness the transition from theoretical concepts to practical solutions.
Hunting for Cyclodextrins: Analytical Assay Methods in Biological FluidsSpeaker: Dr. Tamas Sohajda (Carbohyde) – Dr. Sohajda’s presentation focuses on the detective work involved in studying cyclodextrins within biological matrices. Learn about cutting-edge assay techniques, their role in clinical trials, and the critical insights they provide.
Promising Future for HPBCD in InhalationSpeaker: Dr. Natacha Rocks (Aquilon) – Dr. Rocks will unveil the exciting prospects of hydroxypropyl-β-cyclodextrin (HPBCD) in inhalation therapies. From lung-targeted drug delivery to patient-friendly devices, witness how cyclodextrins are poised to transform respiratory medicine.
Who Should Attend: Researchers, clinicians, pharmaceutical professionals, and anyone curious about the journey of cyclodextrins—from lab discoveries to patient impact.
Don’t miss this opportunity to explore the bridge between science and healing. Register now and join the cyclodextrin revolution!
I would be delighted to hear suggestions for upcoming topics and engage in Q&A, so please feel free to add your impressions in the comments or via email at tamas.sohajda@carbohyde.com. Thank you.
In the coming weeks, we will continue focusing on using cyclodextrins as active ingredients, disease by disease. Stay tuned!
